Teixeira Luis, Barry Sonia, Debourdeau Philippe, Cohen Ariel, Tournigand Christophe
Service de Médecine Interne et Oncologie Médicale, Hôpital Saint-Antoine, Paris, 184, rue du Faubourg Saint-Antoine, 75571 Paris Cedex 12.
Bull Cancer. 2004 Nov;91 Suppl 3:154-8.
5-fluorouracil (5FU) is a largely employed antimetabolite, responsible for several well-known toxicities like hand-foot syndrome, diarrhoea, mucositis or leucopenia. Cardiotoxicity of 5-FU is known but uncommon and usually not life-threatening. The incidence has varied from 1.5 and 18%. The physiopathology is controversial, although more recent data suggest a myocardial toxicity. Clinical presentation include chest-pain, cardiac arrythmia, myocardial infarction or global cardiac failure. Electrocardiographic features are usually aspecific, with ischemic signs. The main treatment is to stop the 5-FU infusion and to introduce symptomatic cardiologic treatment. Although the prognosis is good, the mortality ranges between 2.2 and 13% in case of symptomatic cardiotoxicity. Secondary prophylaxis remains controversial.
5-氟尿嘧啶(5FU)是一种广泛应用的抗代谢药物,会引发多种众所周知的毒性反应,如手足综合征、腹泻、粘膜炎或白细胞减少症。5-氟尿嘧啶的心脏毒性虽为人所知,但并不常见,通常也不会危及生命。其发生率在1.5%至18%之间。尽管最近的数据表明存在心肌毒性,但生理病理学仍存在争议。临床表现包括胸痛、心律失常、心肌梗死或全心衰竭。心电图特征通常不具特异性,伴有缺血迹象。主要治疗方法是停止5-氟尿嘧啶输注,并进行对症心脏治疗。尽管预后良好,但有症状的心脏毒性患者的死亡率在2.2%至13%之间。二级预防仍存在争议。